AKESO(HK:09926) Zhi Tong Cai Jing·2025-07-31 03:30Core Viewpoint - Kangfang Biopharma (09926) has seen a significant stock price increase, reaching a new historical high, driven by the announcement of its innovative PD-1/VEGF bispecific antibody drug, Ivosidenib, entering a pivotal Phase III clinical trial for treating advanced non-small cell lung cancer (NSCLC) [1] Group 1: Company Developments - Kangfang Biopharma's Ivosidenib, a globally first PD-1/VEGF bispecific antibody, has commenced its first patient dosing in a pivotal Phase III clinical study (AK112-305/HARMONi-8A) for patients with locally advanced or metastatic NSCLC who have failed prior PD-1/L1 inhibitors and platinum-based chemotherapy [1] - This marks the seventh Phase III study for Ivosidenib in the lung cancer field, with three of these being international multicenter registrations [1] - Ivosidenib has achieved comprehensive coverage of core indications in the NSCLC field, positioning the company to potentially reshape the overall treatment landscape for advanced NSCLC [1] Group 2: Strategic Importance - Ivosidenib serves as a cornerstone drug in the company's "IO+ADC" 2.0 strategy, focusing on core immuno-oncology indications with a series of ongoing Phase III and Phase II clinical trials [1]